Form 4: Fennec Pharmaceuticals CFO Exercises Stock Options, Acquires Shares

Fennec Pharmaceuticals' Chief Financial Officer, Robert Andrade, exercised stock options to acquire 15,816 common shares at $2.45 per share.

Summary

• Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals, exercised stock options on November 18, 2024.
• This transaction resulted in the acquisition of 15,816 common shares at a price of $2.45 per share.
• Following the transaction, Mr. Andrade directly owns 127,381 common shares.
• The exercised options were part of a grant from July 5, 2016, with an expiration date of July 5, 2026.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation. It is neither particularly positive nor negative, but indicates normal business operations.

Positives

• The exercise of stock options by a key executive can be seen as a positive sign of confidence in the company's future.

Industry Context

This is a routine filing related to executive compensation and is common in publicly traded companies.

Comparison to Industry Standards

• Stock option exercises are a standard form of compensation for executives in publicly traded companies.
• The terms of the options, such as the strike price and expiration date, are typical for such grants.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it increases the number of outstanding shares.

Key Dates

Keywords

stock options, insider trading, executive compensation, share acquisition, Fennec Pharmaceuticals, Robert Andrade, FENC